Health
Bristol Says New Version of Opdivo on Track to Meet Target
Bristol Myers Squibb Co. Opdivo immunotherapy medication is administered to a patient intravenously during cancer treatment in Provo, Utah.
Photographer: George Frey/BloombergBristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it’s on course to meet the company’s goal of adoption by at least 30% of patients in two years.
“We’re really seeing nice uptake and conversion,” Chief Commercialization Officer Adam Lenkowsky said in an interview on the sidelines of the JPMorgan Healthcare conference. “We’re seeing that across a multitude of tumor types.”